Herbert Gritsch

925 total citations
37 papers, 686 citations indexed

About

Herbert Gritsch is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Herbert Gritsch has authored 37 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 8 papers in Genetics and 7 papers in Immunology. Recurrent topics in Herbert Gritsch's work include Platelet Disorders and Treatments (26 papers), Hemophilia Treatment and Research (22 papers) and Blood Coagulation and Thrombosis Mechanisms (14 papers). Herbert Gritsch is often cited by papers focused on Platelet Disorders and Treatments (26 papers), Hemophilia Treatment and Research (22 papers) and Blood Coagulation and Thrombosis Mechanisms (14 papers). Herbert Gritsch collaborates with scholars based in Austria, United States and United Kingdom. Herbert Gritsch's co-authors include Peter L. Turecek, Katalin Váradi, H. P. Schwarz, Wilfried Auer, Ludwig Pichler, Artur Mitterer, Hanspeter Rottensteiner, Friedrich Scheiflinger, Gerald Schrenk and Hans Peter Schwarz and has published in prestigious journals such as Blood, Journal of Pharmacology and Experimental Therapeutics and British Journal of Haematology.

In The Last Decade

Herbert Gritsch

35 papers receiving 645 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Herbert Gritsch Austria 13 599 128 89 76 56 37 686
Julie Pegon France 6 236 0.4× 54 0.4× 132 1.5× 79 1.0× 27 0.5× 7 357
Ria C. Boertjes Netherlands 6 246 0.4× 74 0.6× 72 0.8× 35 0.5× 52 0.9× 6 355
Alexandre Slater United Kingdom 13 215 0.4× 47 0.4× 45 0.5× 67 0.9× 32 0.6× 27 342
S. W. PIPE United States 9 433 0.7× 98 0.8× 16 0.2× 143 1.9× 44 0.8× 13 541
Jean Pierre Marie France 11 186 0.3× 56 0.4× 37 0.4× 130 1.7× 18 0.3× 19 405
Elizabeth H. Cull United States 9 117 0.2× 20 0.2× 48 0.5× 101 1.3× 14 0.3× 27 272
Elien Roose Belgium 12 207 0.3× 185 1.4× 339 3.8× 26 0.3× 16 0.3× 28 411
Ivan Peyron France 14 266 0.4× 54 0.4× 103 1.2× 90 1.2× 20 0.4× 36 397
PD Emanuel United States 5 221 0.4× 136 1.1× 66 0.7× 68 0.9× 20 0.4× 9 331
Beatriz Aguado Spain 9 127 0.2× 40 0.3× 19 0.2× 82 1.1× 28 0.5× 22 215

Countries citing papers authored by Herbert Gritsch

Since Specialization
Citations

This map shows the geographic impact of Herbert Gritsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herbert Gritsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herbert Gritsch more than expected).

Fields of papers citing papers by Herbert Gritsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herbert Gritsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herbert Gritsch. The network helps show where Herbert Gritsch may publish in the future.

Co-authorship network of co-authors of Herbert Gritsch

This figure shows the co-authorship network connecting the top 25 collaborators of Herbert Gritsch. A scholar is included among the top collaborators of Herbert Gritsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herbert Gritsch. Herbert Gritsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Holik, Ann‐Katrin, et al.. (2024). An Automated pre-Dilution Setup for Von Willebrand Factor Activity Assays. BIO-PROTOCOL. 14(1352). e5059–e5059. 1 indexed citations
2.
Rossato, Paolo, Helmut Glantschnig, Fabio Canneva, et al.. (2023). Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease. Journal of Thrombosis and Haemostasis. 21(2). 269–275. 5 indexed citations
3.
4.
Schrenk, Gerald, et al.. (2022). Selective human factor VIII activity measurement after analytical in‐line purification. Research and Practice in Thrombosis and Haemostasis. 6(7). e12821–e12821. 1 indexed citations
5.
Gritsch, Herbert, et al.. (2022). Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease. Journal of Blood Medicine. Volume 13. 649–662. 11 indexed citations
6.
Rossato, Paolo, Enrica Federti, Alessandro Mattè, et al.. (2022). Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Haematologica. 107(11). 2650–2660. 13 indexed citations
7.
Gritsch, Herbert, Margit Stimpfl, & Peter L. Turecek. (2022). Von Willebrand Factor Multimer Analysis by Low Resolution SDS-Agarose Gel Electrophoresis. BIO-PROTOCOL. 12(16). e4495–e4495. 2 indexed citations
8.
Turecek, Peter L., Savita Rangarajan, Michael Laffan, et al.. (2021). Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thrombosis Research. 201. 100–112. 34 indexed citations
9.
Glantschnig, Helmut, Michael Dockal, Veronika Ehrlich, et al.. (2019). Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys. Journal of Pharmacology and Experimental Therapeutics. 371(1). 95–105. 3 indexed citations
10.
Valentino, Leonard A., Peter L. Turecek, Herbert Gritsch, Saulius Butenas, & Kenneth G. Mann. (2018). Issues complicating precision dosing for factor VIII prophylaxis. Transfusion and Apheresis Science. 57(4). 472–479. 8 indexed citations
11.
12.
Turecek, Peter L., Srilatha Tangada, Herbert Gritsch, et al.. (2015). Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes. Expert Review of Clinical Pharmacology. 8(2). 163–177. 6 indexed citations
13.
Dietrich, Barbara, Hanspeter Rottensteiner, Wilfried Auer, et al.. (2010). Preclinical Testing of Human Recombinant von Willebrand Factor: ADAMTS13 Cleavage Capacity in Animals as Criterion for Species Suitability. Seminars in Thrombosis and Hemostasis. 36(5). 522–528. 11 indexed citations
14.
Turecek, Peter L., Artur Mitterer, Herbert Gritsch, et al.. (2006). Biochemical and Functional Characterization of a Serum-Free rVWF Drug Candidate.. Blood. 108(11). 1017–1017. 2 indexed citations
15.
Turecek, Peter L., Katalin Váradi, Herbert Gritsch, & H. P. Schwarz. (2004). FEIBA®: mode of action. Haemophilia. 10(s2). 3–9. 118 indexed citations
16.
Turecek, Peter L., Christian Fiedler, Klaus F. Zimmermann, et al.. (2003). Evaluation of the haemostatic potential of factor VIII‐heparin cofactor II hybrid proteins in a mouse model. British Journal of Haematology. 123(4). 692–695. 3 indexed citations
17.
Schwarz, Hans Peter, Uwe Schlokat, Artur Mitterer, et al.. (2002). Recombinant von Willebrand Factor-Insight into Structure and Function through Infusion Studies in Animals with Severe von Willebrand Disease. Seminars in Thrombosis and Hemostasis. 28(2). 215–226. 12 indexed citations
18.
Plaimauer, Barbara, Uwe Schlokat, Peter L. Turecek, et al.. (2001). Recombinant von Willebrand Factor: Preclinical Development. Seminars in Thrombosis and Hemostasis. 27(4). 395–404. 16 indexed citations
19.
Thomas, K. B., et al.. (1999). Continuous infusion of FVIII and FIX concentrates:in vitroanalysis of clinically relevant parameters. Haemophilia. 5(1). 17–25. 8 indexed citations
20.
Turecek, Peter L., Katalin Váradi, Herbert Gritsch, et al.. (1999). Factor Xa and Prothrombin: Mechanism of Action of FEIBA. Vox Sanguinis. 77(S1). 72–79.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Pegon Breakdown of academic impact, for papers by Ria C. Boertjes Breakdown of academic impact, for papers by Alexandre Slater Breakdown of academic impact, for papers by S. W. PIPE Breakdown of academic impact, for papers by Jean Pierre Marie Breakdown of academic impact, for papers by Elizabeth H. Cull Breakdown of academic impact, for papers by Elien Roose Breakdown of academic impact, for papers by Ivan Peyron Breakdown of academic impact, for papers by PD Emanuel Breakdown of academic impact, for papers by Beatriz Aguado
Rankless by CCL
2026